TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05688371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose morphine
Description: Receiving 0.05 mg morphine/kg as a bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose morphine plus dexmedetomidine
Description: Receiving 0.02 mg morphine/kg as a bolus dose + 0.2 microgram/kg dexmedetomidine
Study: NCT06506240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Treatment will be administered by licensed practitioners with over five years of experience, in separate rooms to prevent patient interaction. The selected acupuncture points include LI11 (Quchi), SP10 (Xuehai), ST36 (Zusanli), SP6 (Sanyinjiao), LR3 (Taichong), LI4 (Hegu), ST25 (Tianshu), CV4 (Guanyuan), GV20 (Baihui), and superior GV29 (superior Yintang). Patients will receive acupuncture or sham acupuncture three times weekly for 6 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Treatment will be administered by licensed practitioners with over five years of experience, in separate rooms to prevent patient interaction. The selected acupuncture points include LI11 (Quchi), SP10 (Xuehai), ST36 (Zusanli), SP6 (Sanyinjiao), LR3 (Taichong), LI4 (Hegu), ST25 (Tianshu), CV4 (Guanyuan), GV20 (Baihui), and superior GV29 (superior Yintang). Patients will receive acupuncture or sham acupuncture three times weekly for 6 weeks.
Study: NCT06576193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Dates for Young Parents (SDYP)
Description: SDYP is a healthy relationship and intimate partner violence (IPV) prevention program, adapted from Safe Dates (Foshee et al., 1998; Foshee et al., 1996) designed for teens, that focuses on pregnant or parenting females. The program consists of ten group-based sessions (50 minutes each) led by a trained facilitator which include interactive discussions, analysis of scenarios, games, role-plays, brainstorming, and a poster contest and theatrical play.
Study: NCT06650150

Intervention type: DIAGNOSTIC_TEST
Intervention: maximal inspiratory pressure
Description: maximal inspiratory pressure (mip) will be measured with a specific device

Intervention type: DIAGNOSTIC_TEST
Intervention: maximal inspiratory pressure
Description: maximal inspiratory pressure (mip) will be measured with a specific device

Intervention type: DIAGNOSTIC_TEST
Intervention: maximal inspiratory pressure
Description: maximal inspiratory pressure (mip) will be measured with a specific device

Intervention type: DIAGNOSTIC_TEST
Intervention: maximal expiratory pressure
Description: MEP will be measured with a specific device

Intervention type: DIAGNOSTIC_TEST
Intervention: maximal expiratory pressure
Description: MEP will be measured with a specific device

Intervention type: DIAGNOSTIC_TEST
Intervention: maximal expiratory pressure
Description: MEP will be measured with a specific device

Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minute walk test
Description: 6mwt will be done by a phsyotherapist

Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minute walk test
Description: 6mwt will be done by a phsyotherapist

Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minute walk test
Description: 6mwt will be done by a phsyotherapist
Study: NCT04573140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Description: The Phase I Stratum 1 dose-escalation study will be performed in up to 28 adult participants using a 3+3 design with an initial embedded accelerated titration design (ATD) to efficiently identify the maximally tolerated dose (MTD). For the initial ATD, patients will be enrolled and treated in cohorts of size 1 starting at dose level -4 to dose level -1 and will expand to a cohort size of 3 after the first DLT is observed or at dose level 0. There are 8 dose levels to potentially be assessed including the possibility of 4 dose levels for the ATD and 4 for the 3+3.~Phase I pediatric (Stratum 2) will be performed in up to 24 pediatric participants. The pediatric dose escalation will follow the 3+3 design starting at dose level -4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Description: The Phase I Stratum 1 dose-escalation study will be performed in up to 28 adult participants using a 3+3 design with an initial embedded accelerated titration design (ATD) to efficiently identify the maximally tolerated dose (MTD). For the initial ATD, patients will be enrolled and treated in cohorts of size 1 starting at dose level -4 to dose level -1 and will expand to a cohort size of 3 after the first DLT is observed or at dose level 0. There are 8 dose levels to potentially be assessed including the possibility of 4 dose levels for the ATD and 4 for the 3+3.~Phase I pediatric (Stratum 2) will be performed in up to 24 pediatric participants. The pediatric dose escalation will follow the 3+3 design starting at dose level -4.
Study: NCT06091930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765049
Description: BI 765049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765049
Description: BI 765049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765049
Description: BI 765049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765049
Description: BI 765049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab
Study: NCT06419946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
Study: NCT01047072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Given orally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transplantation
Study: NCT05986019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial focused ultrasound (tFUS)
Description: Transcranial focused ultrasound (tFUS) is a promising new technology that is both noninvasive and may be focally applied to deep brain targets. tFUS utilizes transducers which contain piezoelectric elements to produce pulses of ultrasonic waves that summate deep in the brain. Transcranial focused ultrasound (tFUS) uses a single transducer fixed in a head-worn apparatus on the scalp to produce ultrasonic waves deep into the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial focused ultrasound (tFUS)
Description: Transcranial focused ultrasound (tFUS) is a promising new technology that is both noninvasive and may be focally applied to deep brain targets. tFUS utilizes transducers which contain piezoelectric elements to produce pulses of ultrasonic waves that summate deep in the brain. Transcranial focused ultrasound (tFUS) uses a single transducer fixed in a head-worn apparatus on the scalp to produce ultrasonic waves deep into the brain.
Study: NCT06263257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandala Art Therapy
Description: In art therapy, visual arts (such as drawing, painting, and sculpting) can be used as a tool to facilitate the expression of emotions and enhance coping skills. Naisin and colleagues (2006) reported that a one-hour art therapy session significantly reduced anxiety levels in hospitalized adult oncology patients. The word mandala is now typically associated with circular, geometric designs and often appears in adult coloring books aimed at promoting mindfulness and stress reduction. However, the methodology and theory of Jung related to mandalas are based not only on coloring pre-drawn templates but also on the activity of creating mandalas. The act of creating a mandala is claimed to provide immediate benefits in improving mood. The mandala is expressed as an instantaneous outward expression of the inner world of the person drawing it.
Study: NCT05518825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel/Nutridrink Compact Protein
Description: Twice daily serving of the study product
Study: NCT04705974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block
Description: Fascia iliaca block will be performed under ultrasound guidenance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: Femoral nerve block will be performed under ultrasound guidenance.
Study: NCT05770804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to face education
Description: Face-to-face training was provided and supported by booklets.
Study: NCT05002660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1 (Intervention)
Description: The investigators will evaluate the efficacy of the CC curriculum in a 24-months community-based randomized controlled trial. They will compare changes in CVD-related anthropometric, behavioral, and psychosocial parameters between subjects in intervention and control communities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2 (Control)
Description: Group 2 will be offered the same activities as Group 1 after the conclusion of the research study.
Study: NCT06105580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing
Description: Conduction system pacing implant as a Resynchronization therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Biventricular pacing implant
Study: NCT04589364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)
Description: injection of toxin on facial muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)
Description: injection of toxin on facial muscle
Study: NCT04705974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block (PENG block)
Description: Pericapsular nerve group block (PENG block) will be performed under ultrasound guidenance.
Study: NCT05708027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic surgical ablation
Description: Thoracoscopic surgical ablation is a minimally invasive procedure used to treat atrial fibrillation by creation Box Lesion Set using Radio Frequency Energy. Pulmonary veins isolation was performed using ablation clamps, whereas isolation of the posterior left atrium (box) was performed using a clamping Medtronic or a linear nonclamping AtriCure device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic surgical ablation
Description: Thoracoscopic surgical ablation is a minimally invasive procedure used to treat atrial fibrillation by creation Box Lesion Set using Radio Frequency Energy. Pulmonary veins isolation was performed using ablation clamps, whereas isolation of the posterior left atrium (box) was performed using a clamping Medtronic or a linear nonclamping AtriCure device.
Study: NCT04840576

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular waterproof sterile dressing.
Description: Waterproof sterile dressing OPSITE Post-Op Visible, Smith \& Nephew, UK

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic Negative Pressure Dressing
Description: Negative wound pressure dressing: PICO-7, Smith \& Nephew, UK
Study: NCT06394804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Starting Dose 3.2 mg BIW for 3 of 4 weeks, Dose -1, 2.4 mg BIW for 3 of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Starting Dose 200 mg BID for 3 of 4 weeks, Dose -1, 200 mg QD for 3 of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg PO daily
Study: NCT05507827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
Description: CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treg CD34+HSPC (Orca-T)
Description: Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
Study: NCT05875467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SE3 Game
Description: A prototype online game designed to increase environmental health literacy
Study: NCT06182579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiMO-401
Description: • Single intratumoral injection of RiMO-401 followed by palliative radiotherapy
Study: NCT06183216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV13
Description: 0.5 mL dose of Sinovac PCV13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV13
Description: 0.5 mL dose of Sinovac PCV13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PREVNAR 13
Description: 0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PREVNAR 13
Description: 0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
Study: NCT06684639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-CAR-T cell
Description: Split intravenous infusion of GD2-CAR-T cells \[dose escalating infusion of (1-100)x10\^6 GD2-CAR-T cells/kg\]
Study: NCT06699732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self Compassion Therapy
Description: Mindful Self-Compassion (MSC) therapy is an 8-week program blending mindfulness and self-compassion to improve emotional resilience and well-being.~Week 1: Introduction - Learn the basics of mindfulness, self-compassion, and reframing self-critical thoughts with kindness.~Week 2: Mindfulness - Practice observing thoughts and emotions without judgment to build self-awareness.~Week 3: Self-Kindness - Develop skills to treat yourself with warmth and care during difficult times.~Week 4: Common Humanity - Explore shared human experiences to reduce feelings of isolation.~Week 5: Working with Challenges - Learn strategies to respond compassionately to emotional pain.~Week 6: Growing Compassion - Deepen compassion for yourself and others through guided exercises.~Week 7: Resilience Building - Strengthen coping skills and foster emotional flexibility.~Week 8: Integration - Consolidate skills to maintain self-compassion in daily life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful Self Compassion Therapy
Description: Mindful Self-Compassion (MSC) therapy is an 8-week program blending mindfulness and self-compassion to improve emotional resilience and well-being.~Week 1: Introduction - Learn the basics of mindfulness, self-compassion, and reframing self-critical thoughts with kindness.~Week 2: Mindfulness - Practice observing thoughts and emotions without judgment to build self-awareness.~Week 3: Self-Kindness - Develop skills to treat yourself with warmth and care during difficult times.~Week 4: Common Humanity - Explore shared human experiences to reduce feelings of isolation.~Week 5: Working with Challenges - Learn strategies to respond compassionately to emotional pain.~Week 6: Growing Compassion - Deepen compassion for yourself and others through guided exercises.~Week 7: Resilience Building - Strengthen coping skills and foster emotional flexibility.~Week 8: Integration - Consolidate skills to maintain self-compassion in daily life.
Study: NCT06701812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.
Study: NCT06743984

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polychromatic resin composite
Description: Polychromatic layering resin composite (enamel and dentin shades).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monochromatic resin composite
Description: Monochromatic resin composite (opaquer and dentin shades)
Study: NCT05463367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
Description: Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
Description: Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids
Description: Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids
Description: Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Study: NCT05722522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Study: NCT05358353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bare Temporary Spur Stent System
Description: Treatment of qualifying infrapopliteal arteries with the Bare Temporary Spur Stent System, in subjects with critical limb ischemia.
Study: NCT05741034

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® VOLITE™
Description: Injection, subdermal and/or intradermal
Study: NCT05630365

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panbio™
Description: The Panbio™ COVID-19/Flu A\&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs
Study: NCT05970497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB707
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB707
Description: Genetically modified herpes simplex type 1 virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opdualag
Description: Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)
Study: NCT04717479

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention (videoconferencing)
Description: 1 hour videoconferencing sessions over 8 weeks with an English language learner partner.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention (videoconferencing)
Description: 1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
Study: NCT04889365

Intervention type: DIAGNOSTIC_TEST
Intervention: SG Diagnostics COVID-19 Antigen Rapid Test Kit
Description: SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)

Intervention type: DIAGNOSTIC_TEST
Intervention: SG Diagnostics COVID-19 Antigen Rapid Test Kit
Description: SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)

Intervention type: DIAGNOSTIC_TEST
Intervention: SG Diagnostics COVID-19 Antigen Rapid Test Kit
Description: SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
Study: NCT04868396

Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Tumor material will be derived from 'left-over' tumor tissue that is not needed for standardised diagnostics (immune histochemistry and molecular testing).
Study: NCT04889365

Intervention type: DIAGNOSTIC_TEST
Intervention: Polymerase chain reaction (PCR) test
Description: Professional collection of a second swab sample, for confirmation by PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Polymerase chain reaction (PCR) test
Description: Professional collection of a second swab sample, for confirmation by PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Polymerase chain reaction (PCR) test
Description: Professional collection of a second swab sample, for confirmation by PCR
Study: NCT06357416

Intervention type: DEVICE
Group type: OTHER
Intervention: MV-POCT Sub-study
Description: Point of care blood testing

Intervention type: OTHER
Group type: OTHER
Intervention: Main Man Van Group Sub-study (MV-Eco)
Description: Consent for long-term follow-up of patients

Intervention type: OTHER
Group type: OTHER
Intervention: MV-QualQ Sub-study
Description: Qualitative questionnaire and interview sub-study